Exelgen Announces Partnerships with Two European Biotechnology Companies
News Jan 02, 2008
Exelgen Ltd. (formerly Tripos Discovery Research) has announced significant new collaborations with two prominent European-based Biotechnology companies. Because of the proprietary nature of the collaborations both companies have declined to be identified or disclose the contract values at this time. One company is a long standing client, the other a new client.
The partnerships encompass a range of collaborative research activities including medicinal chemistry and application of Exelgen’s LeadHopping® technology to identify and progress lead compound series into preclinical studies.
“The decision by these premiere biotechnology companies to select Exelgen as their drug discovery partner underscores the quality of our work, the innovation we bring to our partners and our solid reputation for success in this field," said Mark Warne, Managing Director of Exelgen.
"As we enter 2008, we are committed to expanding our capabilities to provide clients an integrated drug discovery platform from hit identification up through IND enabling studies. We are currently engaged in more high value discovery research programs than ever before, and we look forward to generating excellent results for our clients."
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE